search
Back to results

Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease (VPACS)

Primary Purpose

Sickle Cell-hemoglobin SS Disease, Vaso-occlusive Crisis

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Non invasive positive pressure ventilation
Spirometry
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sickle Cell-hemoglobin SS Disease focused on measuring Non invasive positive pressure ventilation, Spirometry, Acute chest syndrome, Sickle cell disease, Vaso-occlusive crisis

Eligibility Criteria

6 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with SS or S-Beta sickle cell disease aged more than 6 years old and less then 20 years old
  • Hospitalised since less then 24 hours for severe vaso-occlusive crisis (either peripheric localisation or thoracic crisis) with morphinic requirements according to local pain management protocol
  • With a signed informed consent from the patient or his legal representative if the patient is under 18 years old
  • Benefiting of the French social security system

Exclusion Criteria:

  • Patient that has already participated in the study
  • Oxygen requirements, pneumonia, acute chest syndrome or other condition necessitating non invasive ventilation on admission
  • No understanding of spirometry or ventilation techniques
  • Other condition that forbid the use of non invasive ventilation or spirometry as defined by french consensus conference (2006) on non invasive ventilation

Sites / Locations

  • Hôpital Necker - Enfants Malades Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Spirometry

Non invasive positive pressure ventilation

Arm Description

Spirometry

Non invasive positive pressure ventilation

Outcomes

Primary Outcome Measures

Occurence of acute chest syndrome

Secondary Outcome Measures

Pain
Morphinic requirements
Length of hospital stay
Comfort
Quality of sleep

Full Information

First Posted
December 26, 2011
Last Updated
April 9, 2015
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT01501643
Brief Title
Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease
Acronym
VPACS
Official Title
Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease With Vaso-occlusive Crisis and Morphinic Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Terminated
Why Stopped
decision of the promoter
Study Start Date
November 2011 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Acute chest syndrome is a severe respiratory complication of sickle cell disease. The standard prevention of this dangerous complication is spirometry in wich patient is required to take deep breaths trough a little device several times a day. This treatment is compromised when pain in important or when the patient is asleep and cannot participate. The investigators hypothesised that non invasive ventilation in wich patient have no effort to take might be a better prevention than spirometry and may improve pain and quality of sleep. Children with vaso-occlusive crisis necessitating morphinic treatment will be randomly assigned with either spirometry or ventilation and the investigators will monitor for occurrence of acute chest syndrome, pain and quality of sleep.
Detailed Description
Acute chest syndrome is a severe complication of sickle cell disease. Several factors can contribute to this complication including infections, vaso-occlusive crisis, important pain that may give shortness of breath and morphinic treatments as they may cause hypoventilation. The standard prevention of this dangerous complication is incentive spirometry in wich patient is required to take deep breaths trough a little device several times a day. This treatment is compromised when pain in important or when the patient is asleep and cannot participate. In patients who have had surgery who have also pain and morphinic treatments, non invasive ventilation have proven a good option for preventing pulmonary complications. Besides, our experience in non invasive ventilation for treatment of acute chest syndrome show a good tolerance and efficiency. It also seems to help with pain management. The investigators hypothesised that non invasive ventilation in wich patient have no effort to take might be a better prevention than incentive spirometry and may improve pain and quality of sleep. After informed consent, patients aged from 6 to 20 years old with SS or S-Beta sickle cell disease with vaso-occlusive crisis necessitating morphinic treatment hospitalised in intensive care unit in Necker Hospital for Sick Children (Paris) will be randomly assigned with either spirometry or ventilation. It is a monocentric study. Patients with acute chest syndrome, oxygen needs, pneumonia or other condition requiring ventilation at presentation will not be included. Spirometry will be realised through volumetric devices, every two hours during the day with 10 maximum inspirations and at night if the patient is awake. Non invasive ventilation will be applied through a nasal mask with VS III machines from Resmed®, at least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on. The investigators will monitor for occurrence of acute chest syndrome, pain, morphinic requirements, length of hospital stay, comfort, quality of sleep The treatment will be continued until morphinic treatment is stopped. The investigators intend to include 60 patients in each arm to show a difference of 25% in the occurrence of acute chest syndrome (primary judgement criteria). Acute chest syndrome will be defined according to the criteria used by Vichinsky (Vichinsky, E. P. et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 89, 1787-1792 (1997) The investigators will aslo compare morphinic requirements, length of hospital stay and quality of sleep as secondary judgment criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell-hemoglobin SS Disease, Vaso-occlusive Crisis
Keywords
Non invasive positive pressure ventilation, Spirometry, Acute chest syndrome, Sickle cell disease, Vaso-occlusive crisis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Spirometry
Arm Type
Active Comparator
Arm Description
Spirometry
Arm Title
Non invasive positive pressure ventilation
Arm Type
Experimental
Arm Description
Non invasive positive pressure ventilation
Intervention Type
Device
Intervention Name(s)
Non invasive positive pressure ventilation
Intervention Description
At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
Intervention Type
Device
Intervention Name(s)
Spirometry
Intervention Description
Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
Primary Outcome Measure Information:
Title
Occurence of acute chest syndrome
Time Frame
up to 2 months at maximum (duration of hospitalization)
Secondary Outcome Measure Information:
Title
Pain
Time Frame
up to 2 months at maximum (duration of hospitalization)
Title
Morphinic requirements
Time Frame
up to 2 months at maximum (duration of hospitalization)
Title
Length of hospital stay
Time Frame
up to 2 months at maximum (duration of hospitalization)
Title
Comfort
Time Frame
up to 2 months at maximum (duration of hospitalization)
Title
Quality of sleep
Time Frame
up to 2 months at maximum (duration of hospitalization)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with SS or S-Beta sickle cell disease aged more than 6 years old and less then 20 years old Hospitalised since less then 24 hours for severe vaso-occlusive crisis (either peripheric localisation or thoracic crisis) with morphinic requirements according to local pain management protocol With a signed informed consent from the patient or his legal representative if the patient is under 18 years old Benefiting of the French social security system Exclusion Criteria: Patient that has already participated in the study Oxygen requirements, pneumonia, acute chest syndrome or other condition necessitating non invasive ventilation on admission No understanding of spirometry or ventilation techniques Other condition that forbid the use of non invasive ventilation or spirometry as defined by french consensus conference (2006) on non invasive ventilation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claire Heilbronner, MD, PhD
Organizational Affiliation
Necker - Enfants Malades Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Necker - Enfants Malades Hospital
City
Paris
ZIP/Postal Code
75015
Country
France

12. IPD Sharing Statement

Learn more about this trial

Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease

We'll reach out to this number within 24 hrs